Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement Press Release Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement...
Nicox et Glaukos signent un accord exclusif de recherche incluant une option de licence mondiale pour NCX 1728 Communiqué de presseNicox et Glaukos signent un accord exclusif de recherche incluant...
Nicox Announces Approval of ZERVIATE in China Press Release Nicox Announces Approval of ZERVIATE in China Nicox’s partner, Ocumension Therapeutics, has received approval for ZERVIATE® for ocular...
Nicox annonce l’approbation de ZERVIATE en Chine Communiqué de presseNicox annonce l’approbation de ZERVIATE en Chine Ocumension Therapeutics, partenaire licencié de Nicox, a reçu l'approbation...
Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board Press Release Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from...
Nicox nomme Christine Placet administrateur ; Michele Garufi se retire du Conseil d’administration Communiqué de presseNicox nomme Christine Placet administrateur ; Michele Garufi se retire du...
Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470 Press Release Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470...
Nicox : Recrutement du dernier patient aux Etats- Unis dans l’étude clinique de phase 3 Denali sur NCX 470 Communiqué de presseNicox : Recrutement du dernier patient aux Etats-Unis dans l’étude...
Nicox : Participation aux prochaines conférences Communiqué de presseNicox : Participation aux prochaines conférences 19 juillet 2024 – publication at 7H30 CET Sophia Antipolis, FranceNicox SA...
Nicox announces attendance at upcoming conferences Press Release Nicox announces attendance at upcoming conferencesJuly 19th, 2024 – release at 7:30 am CETSophia Antipolis, FranceNicox SA...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.